Literature DB >> 2082151

Cryptic alpha-toxin gene in toxic shock syndrome and septicaemia strains of Staphylococcus aureus.

M O'Reilly1, B Kreiswirth, T J Foster.   

Abstract

The majority of clinical isolates of Staphylococcus aureus that produce toxic shock syndrome toxin-1 (TSST-1) fail to express alpha-toxin, despite having a copy of the hla gene in the chromosome. The hla gene was cloned from an Hla- TSST-1+ strain, Todd 555, which had been isolated from a case of toxic shock syndrome in the USA. Of the 630 bases of the Todd 555 gene sequenced, 46 differed from the hla gene sequence of strain Wood 46. The defect in alpha-toxin expression was shown to be due to a nonsense mutation which converted a CAG glutamine codon in the equivalent position in the functional Wood 46 sequence to a TAG stop codon. The same mutation was present in the hla gene cloned from a human septicaemia strain (V37) isolated in Dublin. The nonsense mutation of Todd 555 was suppressed by the supE44 mutation in Escherichia coli resulting in haemolytic activity in cell lysates. Hybrid hla genes were formed by splicing fragments of hla from Todd 555 and Wood 46. Expression of one such chimaeric hla gene in S. aureus demonstrated that the Todd 555 hla gene has a functional agr-regulated promoter. The silent hla gene may be a cryptic gene in S. aureus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2082151     DOI: 10.1111/j.1365-2958.1990.tb02044.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  20 in total

1.  Staphylococcal superantigens cause lethal pulmonary disease in rabbits.

Authors:  Kristi L Strandberg; Jessica H Rotschafer; Sara M Vetter; Rebecca A Buonpane; David M Kranz; Patrick M Schlievert
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

2.  Effect of non-absorbent intravaginal menstrual/contraceptive products on Staphylococcus aureus and production of the superantigen TSST-1.

Authors:  Patrick M Schlievert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

3.  Proinflammatory exoprotein characterization of toxic shock syndrome Staphylococcus aureus.

Authors:  Ying-Chi Lin; Michele J Anderson; Petra L Kohler; Kristi L Strandberg; Michael E Olson; Alexander R Horswill; Patrick M Schlievert; Marnie L Peterson
Journal:  Biochemistry       Date:  2011-07-21       Impact factor: 3.162

4.  New insights into the prevention of staphylococcal infections and toxic shock syndrome.

Authors:  Ying-Chi Lin; Marnie L Peterson
Journal:  Expert Rev Clin Pharmacol       Date:  2010-11-01       Impact factor: 5.045

5.  Clonal associations among Staphylococcus aureus isolates from various sites of infection.

Authors:  M C Booth; L M Pence; P Mahasreshti; M C Callegan; M S Gilmore
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

6.  Staphylococcal accessory regulator (sar) in conjunction with agr contributes to Staphylococcus aureus virulence in endophthalmitis.

Authors:  M C Booth; A L Cheung; K L Hatter; B D Jett; M C Callegan; M S Gilmore
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  agr function in clinical Staphylococcus aureus isolates.

Authors:  Katrina E Traber; Elsie Lee; Sarah Benson; Rebecca Corrigan; Mariela Cantera; Bo Shopsin; Richard P Novick
Journal:  Microbiology       Date:  2008-08       Impact factor: 2.777

Review 8.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

Review 9.  Alpha-toxin of Staphylococcus aureus.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Microbiol Rev       Date:  1991-12

10.  Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.

Authors:  Joseph J Dajcs; Brett A Thibodeaux; Mary E Marquart; Dalia O Girgis; Mullika Traidej; Richard J O'Callaghan
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.